# Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study

> **NCT00600301** · PHASE3 · WITHDRAWN · sponsor: **Asociación para Evitar la Ceguera en México**

## Conditions studied

- Diffuse Diabetic Macular Edema

## Interventions

- **DRUG:** Triamcinolone Acetonide and Bevacizumab

## Key facts

- **NCT ID:** NCT00600301
- **Lead sponsor:** Asociación para Evitar la Ceguera en México
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-01
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** undefined
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00600301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00600301, "Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00600301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*